Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMT-NK plus pembrolizumab in gemcitabine-refractory biliary tract cancer (Phase 1/2a)
KCT0004324Phase 2Completed
- Sponsor
- SMT bio Co., Ltd.
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SMT-NK and pembrolizumab in biliary cancer, gallbladder cancer and cholangiocarcinoma (CCA), sponsored by SMT bio Co., Ltd. Started Dec 2019; status: completed.
02
Drugs
SMT-NKpembrolizumab
03
Conditions
biliary cancergallbladder cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on KCT0004324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004324.